Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) and OmniAb (NASDAQ:OABI – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, risk and valuation.
Valuation and Earnings
This table compares Astellas Pharma and OmniAb”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Astellas Pharma | $12.56 billion | N/A | $334.93 million | $0.30 | 36.40 |
| OmniAb | $26.39 million | 9.00 | -$62.03 million | ($0.60) | -2.75 |
Profitability
This table compares Astellas Pharma and OmniAb’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Astellas Pharma | 4.34% | 19.67% | 8.71% |
| OmniAb | -275.83% | -22.79% | -20.18% |
Risk and Volatility
Astellas Pharma has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, OmniAb has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500.
Institutional & Insider Ownership
72.1% of OmniAb shares are held by institutional investors. 8.6% of OmniAb shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and price targets for Astellas Pharma and OmniAb, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Astellas Pharma | 0 | 1 | 0 | 1 | 3.00 |
| OmniAb | 1 | 0 | 3 | 0 | 2.50 |
OmniAb has a consensus target price of $6.67, indicating a potential upside of 304.04%. Given OmniAb’s higher possible upside, analysts clearly believe OmniAb is more favorable than Astellas Pharma.
Summary
Astellas Pharma beats OmniAb on 10 of the 14 factors compared between the two stocks.
About Astellas Pharma
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex’s GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.
About OmniAb
OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
